Multivariate Analysis and Prediction of Hypertensive Disorder Complicating Pregnancy and Its Related Mechanism

Launched by FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY · May 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a condition called hypertensive disorder complicating pregnancy (HDP), which affects around 5% to 8% of pregnant women worldwide. HDP can pose serious risks to both mothers and their babies, which makes understanding and predicting it very important. The researchers want to find specific markers in the body that could help identify women at risk for HDP early in their pregnancy. They believe that changes in the gut bacteria of pregnant women may play a role in this condition, and they will analyze blood, stool, and tissue samples to uncover these potential links.

To participate in this study, women must be pregnant with a single baby and meet certain medical criteria related to HDP. However, those with certain health issues, like severe heart conditions or mental illnesses, or those who have recently taken certain medications, won't be eligible. If you take part in the trial, you will provide samples and undergo assessments that will help researchers learn more about HDP, potentially leading to better prevention and treatment options in the future. The study is set to begin recruiting participants in July 2024 and will continue until July 2027.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. singleton pregnancy;
• • 2. Those who meet the relevant diagnostic criteria in Guidelines for the Diagnosis and Treatment of Hypertensive Disorders during Pregnancy (2020).
• Exclusion Criteria:
• • 1. Patients with severe cardiovascular diseases, blood system diseases and organ damage before pregnancy;
• • 2. Persons with severe mental illness;
• • 3. Pregnant women who gave birth to children with birth defects in pregnancy outcome;
• • 4. Patients who are not suitable for taking blood samples, such as anemia;
• • 5. Patients who are in an emergency during operation and are difficult to take tissue samples;
• • 6. Patients with chronic hypertension complicated with pregnancy;
• • 7. History of taking antibiotics, immunotoxic drugs, hormone antagonists and large doses of probiotics within 3 months;
• • 8. Patients who refused to participate in the trial.